chufangao/CTO huggingface dataset:
Clinical trial NCT04629703: Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Official title: Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor: Rigel Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 280.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-25
Primary completion date: 2022-09-05
Completion date: 2022-09-05
Clinical trial NCT04773067: A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers
Official title: A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers
Sponsor: United Biomedical Inc., Asia (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Under the limited resources, to re-plan the ongoing clinical trials of this product.
Enrollment: 3877.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-30
Primary completion date: 2022-03-08
Completion date: 2022-03-08
Clinical trial NCT03235752: Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis
Official title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis
Sponsor: I-Mab Biopharma HongKong Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 91.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-02-06
Primary completion date: 2020-12-21
Completion date: 2020-12-21
Plan to share individual participant data: NO
Clinical trial NCT02957032: A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Official title: A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Sponsor: Philogen S.p.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: New agents for the same indication impacted on patients' recruitment
Enrollment: 30.0 (ESTIMATED)
Number of arms: 1.0
Start date: 2016-04-13
Primary completion date: 2023-09-29
Completion date: 2023-09-29
Clinical trial NCT03294694: Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Official title: A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer
Sponsor: Dana-Farber Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Safety Implications
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-08
Primary completion date: 2020-10-14
Completion date: 2020-10-14
Plan to share individual participant data: NO
Clinical trial NCT01845441: Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions
Official title: A Randomized, Controlled Trial on Dexmedetomidine for Providing Adequate Sedation and Preserved Neurologic Examination for Endovascular Treatment of Acute Ischemic Stroke or Cerebral Vasospasm.
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The principal investigator left employment at the sponsoring Institution
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-04-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04205643: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)
Official title: A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 548.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-01
Primary completion date: 2022-07-07
Completion date: 2023-07-11
Baseline population: All-randomized population
Clinical trial NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Official title: A Phase II, Single-Arm Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-06
Primary completion date: 2023-11-17
Completion date: 2023-11-17
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02944864: A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Official title: Phase I Study of Tolerance and Pharmacokinetics of TQ-B3395 in Patients With Advanced Cancer
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Per sponsor request.
Enrollment: 53.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-13
Primary completion date: 2021-05-23
Completion date: 2022-09-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02981173: Psilocybin for the Treatment of Cluster Headache
Official title: Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-12-05
Primary completion date: 2022-06-30
Completion date: 2022-10-21
Plan to share individual participant data: NO
Clinical trial NCT03752190: Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers
Official title: Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Change in personnel leading to inability to conduct study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-31
Primary completion date: 2020-09-30
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT05210517: SGLT2 Inhibition: Uric Acid Excretion Study
Official title: Uric Acid Excretion Study: Open-label Randomised Cross Over Study
Acronym: UREX
Sponsor: Amsterdam UMC, location VUmc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-10-01
Primary completion date: 2021-06-08
Completion date: 2021-09-01
Plan to share individual participant data: NO
Clinical trial NCT05184101: Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)
Official title: INHALEd Nebulised Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 (INHALE-HEP) Australia
Acronym: INHALE-HEP
Sponsor: Australian National University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: COVID-19 hospitalisations limited in Australia, unable to recruit patients due to low numbers of hospitalisations.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-31
Primary completion date: 2023-12-01
Completion date: 2024-03-01
Plan to share individual participant data: YES
IPD sharing description: Planned international meta-trial see NCT04635241
IPD time frame: real-time
Clinical trial NCT04427540: Oxytocin Pharmacokinetics After Intramuscular Injection
Official title: Oxytocin Pharmacokinetics After Intramuscular Injection
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study was not initiated; no subjects were consented or enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-31
Primary completion date: 2022-06-30
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04911790: Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults
Official title: Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 18 Years and Older: A Multicenter,Open-label Study
Sponsor: Sinovac Biotech Co., Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 131650.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-05
Primary completion date: 2023-01-02
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT00669669: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Official title: Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Terminated due to loss in funding.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2009-02-25
Primary completion date: 2018-07-06
Completion date: 2021-01-20
Clinical trial NCT05820152: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
Official title: A Phase 1/2, Multi-regional, Single-Arm, Open-Label, Dose-Finding Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Gene Therapy for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND1 Mutation
Sponsor: Neurophth Therapeutics Inc (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Due to the sponsor circumstances and external reasons
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-08-15
Primary completion date: 2024-06-24
Completion date: 2024-06-24
Plan to share individual participant data: NO
Clinical trial NCT05304130: A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
Official title: A Single Center, Single Dose, Open-label Study in Healthy Japanese Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Otilimab
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: This study was cancelled because of the limited efficacy demonstrated in the ContRAst phase III programme as a potential treatment for rheumatoid arthritis. GSK has decided not to progress with regulatory submissions
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-08
Primary completion date: 2023-05-04
Completion date: 2023-05-04
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT05467761: Bioavailability Study of Psilocybin in Normal Adults
Official title: A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor was not financially able or willing to continue to support the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-06-30
Primary completion date: 2024-03-31
Completion date: 2024-03-31
Plan to share individual participant data: NO
Clinical trial NCT05257148: Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy
Official title: Open-label, Multicenter, Multinational, Interventional Clinical Trial to Assess Effectiveness and SAfety of the Extemporaneous Combination of Nebivolol and Zofenopril Calcium in Grade 1 to 2 Hypertensive patIents Versus Each mOnotherapy
Acronym: Masaccio
Sponsor: Menarini International Operations Luxembourg SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 283.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-26
Primary completion date: 2021-12-22
Completion date: 2021-12-22
Baseline population: Intentio to treat population
Plan to share individual participant data: NO
Clinical trial NCT05321498: Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Official title: A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of Inflammation
Sponsor: Inmune Bio, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: MCI patients will now be enrolled in the XPro1595-AD-02 study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-06-30
Primary completion date: 2023-10-26
Completion date: 2023-10-26
Plan to share individual participant data: NO
Clinical trial NCT03763422: Trial in Low Grade Glioma Patients: Wait or Treat
Official title: IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study
Acronym: IWOT
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Poorly recruiting
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-03-16
Primary completion date: 2021-12-29
Completion date: 2021-12-29
Clinical trial NCT03497598: Preventing Recurrent Urinary Tract Infections With α-D-mannose
Official title: Preventing Recurrent Urinary Tract Infections With α-D-mannose: a Prospective, Randomized, Double-blinded Placebo-controlled Trial
Acronym: PUTIM
Sponsor: Kantonsspital Aarau (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: not enough patients
Enrollment: 15.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-09
Primary completion date: 2020-05-31
Completion date: 2020-05-31
Clinical trial NCT04052204: Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Official title: A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not provide additional clinical benefit over current or future Standard of Care in the different therapeutic indications that this trial was to evaluate.
Enrollment: 3.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-12-30
Primary completion date: 2020-09-29
Completion date: 2020-09-29
Limitations and caveats: Phase 1b part of Combination A was conducted but not completed as company terminated this study on 21 May 2021. Termination was not due to a regulatory request or new emerging safety signals. Test for Combination B, Combination C and Phase 2 expansion for Combination A planned in the protocol were not conducted.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04585932: Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
Official title: Phase 2 Response Evaluation of Finite Systemic Therapy With Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART)
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: At the request of the ad interim Department Chairman due to PI is no longer at institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-24
Primary completion date: 2021-01-08
Completion date: 2021-01-08
Clinical trial NCT04517864: PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
Official title: A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA
Acronym: Allegro2a
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: For business reasons
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-15
Primary completion date: 2022-01-04
Completion date: 2024-05-07
Baseline population: Baseline analysis population included all participants taking at least 1 dose of study intervention.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT03367195: Efficacy and Safety of DLBS2411 in the Management of GERD
Official title: Efficacy and Safety of DLBS2411 Compared to Omeprazole in the Management of Gastroesophageal Reflux Disease (GERD)
Sponsor: Dexa Medica Group (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Very low recruitment rate. The Study Site classifies as tertiary referral hospital. Therefore, GERD Patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-16
Primary completion date: 2020-05-04
Completion date: 2020-09-09
Clinical trial NCT05220293: Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream
Official title: The Effect of Betamethasone Dipropionate on Patients With Eosinophilic Chronic Rhinosinusitis
Acronym: OT-007
Sponsor: Oticara Australia PTY LTD (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Single site study OT-007 re-opened as multi-site OT-007B study
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-02-23
Primary completion date: 2023-12-30
Completion date: 2023-12-30
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available.
Clinical trial NCT03291288: Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Official title: An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 32.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-26
Primary completion date: 2018-09-26
Completion date: 2021-04-16
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT05395260: FL- 101 Study in Non-Metastatic MIBC
Official title: A Pilot Window of Opportunity Trial: FL-101 in Non-Metastatic Muscle Invasive Bladder Cancer
Sponsor: Flame Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-08-22
Primary completion date: 2022-11-28
Completion date: 2022-12-28
Plan to share individual participant data: NO
Clinical trial NCT04868708: A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Official title: A Multicenter, Open-label, Phase II Study of AK104（an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer
Sponsor: Akeso (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 50.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-04-01
Primary completion date: 2024-02-28
Completion date: 2024-02-28
Plan to share individual participant data: NO